ArticleJournal of experimental & clinical cancer research : CR2026
GSPT1-specific protein degradation is effective in preclinical models of chemoresistant MYCN-amplified neuroblastoma.
Article in Journal of experimental & clinical cancer research : CR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHigh-risk neuroblastoma (HR-NB) is associated with therapy-resistant relapse, and novel therapeutic strategies are needed. GSPT1 is a GTPase involved in protein translation whose disruption may offer therapeutic potential in translation-dependent cancers.
methodsGSPT1 expression was assessed in publicly available clinical data and tissue microarrays. GSPT1-degrading molecular glues were tested in MYCN-amplified NB organoids. Cell viability, cell death assays, western blotting, and proteomics were used to evaluate GSPT1 degraders. Effects on tumor growth and mouse survival were benchmarked against standard-of-care chemotherapy in a chemoresistant NB patient-derived xenograft (PDX) model. RNA sequencing and histopathological analysis were used to assess mechanisms of action in vivo.
resultsGSPT1 expression is associated with unfavorable outcomes in NB patients. Single-cell analysis revealed elevated GSPT1 expression in MYCN-amplified NB, whereas the E3 ligase CRBN (essential for protein degradation) was predominantly expressed in NB cells relative to non-malignant cells. GSPT1-specific degradation decreased cell viability and induced apoptosis in MYCN-amplified NB organoids and PDX models. GSPT1 degradation in vivo resulted in NB differentiation and suppression of MYCN and its related core regulatory gene networks. In vivo treatment further outperformed standard-of-care chemotherapy and increased survival in a highly chemoresistant NB PDX model.
conclusionsInhibition of the translational machinery by GSPT1-degrading molecular glues shows therapeutic potential in chemoresistant MYCN-amplified NB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.